neuroendocrine carcinoma
Recently Published Documents


TOTAL DOCUMENTS

3189
(FIVE YEARS 955)

H-INDEX

63
(FIVE YEARS 6)

2022 ◽  
Vol 11 ◽  
Author(s):  
Ying Chen ◽  
Xiaoying Cui ◽  
Di Wang ◽  
Guojie Xia ◽  
Minyan Xing ◽  
...  

PurposeLarge cell neuroendocrine carcinoma (LCNEC) and classic large cell carcinoma (LCC) are two distinct entities with different histological and biological characteristics. However, the mutational profiles and the clinical behavior of the two subtypes of lung cancer remain to be explored.Patients and MethodsPathological diagnoses of all screened patients were finally confirmed by three or four experienced pathologists. Patients with uncertain pathological diagnoses were excluded. Finally, we genetically profiled ten patients with LCNEC and seven with LCC. ALL patients were subjected to next-generation sequencing (NGS) test, which included nine patients sequenced with a 139-gene panel and eight patients with a 425-gene panel. Including only intersected mutations from these two panels, survival analysis was further conducted.ResultsBoth LCNEC and LCC showed high prevalence in male patients, with no clear association with smoking history. Potential targetable mutations in KRAS and RET were detected in the study cohort. However, LCNEC and LCC showed distinct mutational profiles with an enrichment of RB1/TP53 co-mutations in a subset of LCNEC patients. SMARCA4 and KEAP1 mutations were exclusively found in LCC patients, and RICTOR, BRAF, ROS1 and TET2 mutations were only detected in LCNEC. LCC patients in the cohort had shorter survival compared to LCNEC patients (p=0.006). Survival analysis revealed an association between SMARCA4 mutations and poor outcome in the study cohort and in the LCC subset. Mutations in BRAF were associated with a trend of increased survival in the study cohort, as well as in the LCNEC subset. Finally, TET2 mutations were associated with poor outcome in the LCNEC cohort.ConclusionLCC and LCNEC were both heterogeneous diseases with limited treatment options. Our study identified potential targetable mutations and prognostic biomarkers that might provide more therapeutic options and improve individualized patient care.


Author(s):  
Charles A. Keilin ◽  
Kyle K. VanKoevering ◽  
Jonathan B. McHugh ◽  
Erin L. McKean

Abstract Objectives Sinonasal neuroendocrine carcinomas (SNECs) are among the rarest paranasal sinus cancers. Consensus guidelines for therapy are difficult to develop due to limited data regarding the natural history and successful treatment of these tumors. This study presents 15 years of experience treating SNEC at a single institution and a review of the literature. Design Retrospective review. Setting Academic medical center in the United States. Participants Patients diagnosed with primary SNEC. Main Outcome Measures Overall survival. Results Thirteen patients were identified and included. Overall estimated survival was 74.6% at 5 years. Ten of 13 (76.9%) patients were diagnosed with high-grade neuroendocrine carcinoma and three (23.1%) with intermediate or low grade. All three patients with low- or intermediate-grade cancer survived more than 10 years from their initial diagnosis (median survival: 11.6 years) and are currently alive. The four patients who died had high-grade carcinoma, and estimated overall 5-year survival for all patients with high-grade carcinomas was 65.6%. Five patients, all with high-grade carcinoma, of seven who completed primary chemoradiation therapy (CRT) required salvage resection, and 60% are alive without disease. Conclusion This cohort has a higher overall rate of survival than many recent case series and reviews. There is consensus that multimodal therapy is preferred over monotherapy, but approaches to treatment vary widely. Our approach of surgical resection as primary therapy for low-grade tumors and primary CRT for high-grade SNEC has been successful, and could indicate hope for improved survival among these patients.


Author(s):  
Ho-Man Yeung ◽  
Krishnalatha Sreekrishnanilayam ◽  
Caitlin Meeker ◽  
Mengying Deng ◽  
Sonali Agrawal ◽  
...  

Cureus ◽  
2022 ◽  
Author(s):  
Kelsee Felux ◽  
Burke McCarty ◽  
Dennis Turner ◽  
TKeyah Gray ◽  
Vijaykumar Patel

2022 ◽  
Vol 50 (1) ◽  
pp. 030006052110673
Author(s):  
Yunqiang Zhang ◽  
Jingxin Ding ◽  
Keqin Hua

Objective To compare the prognostic value of International Federation of Gynecology and Obstetrics (FIGO) 2009 and 2018 staging systems in surgical patients with small cell neuroendocrine carcinoma of the cervix (SCNEC). Methods We re-staged 64 surgical IB–IIA (FIGO 2009) SCNEC patients according to the FIGO 2018 system and refined stage IIIC of FIGO 2018 based on tumor local invasion. The prognostic factors were analyzed, and the advantages of FIGO 2018 were compared with 2009. Results The 5-year overall survival rate (OS) was 78.5% for stage I and 22.2% for stage II (FIGO 2009). In FIGO 2018, there was no difference between stage I and II, and the 5-year OS was 74.1%, 60.2%, and 0% for stage I/II, IIIC1, and IIIC2. After combining stage IIIC with the local invasion stage (T1 was limited to the cervix and vagina; T2 involved the parametrium; T3 involved the pelvic or abdominal cavity), the 5-year OS for stage IIICT1, IIICT2, and IIICT3 was 83.3%, 30.0%, and 0%, respectively. Conclusions For stage II SCNEC patients, FIGO 2009 underestimated the prognosis, while FIGO 2018 was more accurate. For stage IIIC, FIGO 2018 might be more individualized and accurate after combining stage IIIC with tumor local invasion.


2021 ◽  
Author(s):  
Ziran Yin ◽  
Xiumin Huang

Abstract Background: Neuroendocrine carcinoma of the cervix is rare and aggressive disease, of which prognosis information and the effectiveness of the therapies is unclear.Methods: A retrospective study using data from the SEER database for the first diagnosed Neuroendocrine carcinoma of the cervix patients was conducted. We performed univariate and multivariate Cox models to screen for independent prognostic factors for overall survival. Subgroup analysis and sensitive analysis were performed for further study, then again univariate and multivariate analyses of Cox regression analysis were performed based on the sensitivity analysis data set.Results: A total of 250 Neuroendocrine carcinoma of the cervix cases was included, tumor subtype, age, marriage, race, number of regional lymph nodes, number of positive lymph nodes, radiotherapy, surgery, and FIGO stage were all factors affecting OS, and multivariate analysis identified FIGO staging (HR, 2.4; 95% CI, 1.505-3.828, P < 0.001) and surgery (HR, 0.467; 95% CI, 0.358-0.609, P < 0.001) treatment as independent indicators. With respect to the factors associated with treatments, we found that patients who underwent surgery (yes vs. no vs. unknown) or radiation (yes vs. no) experienced prolonged survival, both P < 0.001Conclusions: Our investigation shows that for patients with NECC surgery seems to be the effective treatment. Chemotherapy cannot improve the prognosis of NECC patients, and the effectiveness of radiation should be further verified.


Sign in / Sign up

Export Citation Format

Share Document